Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Myasthenia Gravis 1

Interventions

pembrolizumab 1281Specimen Handling 927Carboplatin 835Magnetic Resonance Spectroscopy 834Cyclophosphamide 809Cisplatin 733Nivolumab 683Paclitaxel 638Radiotherapy 614Gemcitabine 582Biopsy 558Bevacizumab 482Dexamethasone 446fludarabine 411Docetaxel 385venetoclax 371Oxaliplatin 368Capecitabine 364Fluorouracil 360atezolizumab 346durvalumab 340Rituximab 334Drug Therapy 332Doxorubicin 319Blood Specimen Collection 317Radiosurgery 317Standard of Care 311Pemetrexed 307Ipilimumab 306Radiation 286

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
HBM9161 × 1 year × Clear all
NCT05332210 2026-04-28

Evaluate the Safety of HBM9161 (HL161) Subcutaneous Injection in Patients With Generalized Myasthenia Gravis

Harbour BioMed (Guangzhou) Co. Ltd.

Phase 3 Completed
111 enrolled

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡